TP53, as a tumor suppressor, can trigger cell cycle arrest, aging, and/or apoptosis on cellular stress, and previous studies have shown that the reactivation of TP53 can be used to treat refractory prostate cancer (Yu et al., 2019; Engeland, 2022). This evidence concerns the gene TP53 and neoplasm.